Related Experiment Video

Updated: May 28, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]

N Esser1, N Paquot, A J Scheen

  • 1Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Sart-Tilman, Université de Liège, 4000 Liège, Belgique. nathalie.esser@student.ulg.ac.be

Revue Medicale Suisse
|October 7, 2011
PubMed

Insights

Chronic inflammation links abdominal obesity, insulin resistance, and type 2 diabetes. Anti-inflammatory and antioxidant drugs show potential for preventing and treating type 2 diabetes mellitus.

Area of Science:

  • Endocrinology
  • Metabolic Syndrome Research
  • Diabetes Pathogenesis

Background:

  • Chronic low-grade inflammation is a hallmark of abdominal obesity, insulin resistance, and type 2 diabetes mellitus.
  • Pro-inflammatory cytokines and oxidative stress are implicated in the development of type 2 diabetes.
  • Emerging evidence suggests a potential role for anti-inflammatory interventions in diabetes management.

Purpose of the Study:

  • To review the metabolic effects of anti-inflammatory and antioxidant drugs in patients with metabolic syndrome or type 2 diabetes.
  • To evaluate the therapeutic potential of targeting inflammation and oxidative stress in type 2 diabetes.
  • To synthesize findings from studies investigating specific anti-inflammatory agents and antioxidants.

Main Methods:

  • Review of clinical studies examining the metabolic impact of anti-inflammatory drugs (salicylates, IL-1 antagonists, TNF-alpha antagonists).
  • Analysis of research on antioxidant drugs (e.g., succinobucol) in patients with metabolic disorders.
  • Focus on studies involving individuals diagnosed with metabolic syndrome or type 2 diabetes mellitus.

Main Results:

  • Studies explored the efficacy of salicylates, interleukin-1 antagonists, and tumor necrosis factor-alpha antagonists in improving metabolic parameters.
  • Research investigated the effects of antioxidants like succinobucol on metabolic health in relevant patient populations.
  • Findings provide insights into the metabolic benefits and challenges of anti-inflammatory and antioxidant therapies.

Conclusions:

  • Anti-inflammatory and antioxidant strategies warrant further investigation for their role in managing type 2 diabetes.
  • Targeting inflammation and oxidative stress may offer novel therapeutic avenues for metabolic syndrome and diabetes.
  • Clinical application of these agents requires careful consideration of their metabolic effects and patient outcomes.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...